MyMD Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc. is a U.S. clinical-stage biopharmaceutical company that has historically focused on developing novel therapies for age-related disorders, autoimmune diseases, and inflammatory conditions. The company was organized under the laws of Florida in November 2014, initially to develop and commercialize technology and patent rights around its MYMD-1 program. It later became a publicly traded company through a merger transaction with Akers Biosciences, after which the combined entity carried the MyMD Pharmaceuticals name and traded on the NASDAQ in the United States. More recently, the corporate story continued under a new market identity: in July 2024, the company announced that it would begin trading under the new ticker TNFA, reflecting a rebranding from MyMD Pharmaceuticals to TNF Pharmaceuticals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1321834/000149315223010384/form10-k.htm)) From a business-model perspective, MyMD has been centered on two therapeutic platforms rather than a broad commercial product portfolio. Its lead historical platform, MYMD-1, is a small-molecule program designed to regulate the immunometabolic system by controlling TNF-α and other pro-inflammatory cytokines. The company has also described a second platform aimed at healthier aging and disease-modifying interventions in inflammatory and autoimmune settings. This makes MyMD a classic early-stage biotech story: the value proposition depends primarily on scientific validation, clinical data generation, regulatory progress, and access to capital, not on established sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1321834/000149315220022836/form425.htm?utm_source=openai)) The development timeline shows that substantive operations began in 2016, the company filed an IND with the U.S. FDA in December 2018, and it completed its first-in-human Phase 1 clinical trial in December 2019. Those milestones matter because they indicate the company has moved beyond pure discovery, but it still remains far from the cash-flow profile of a commercial-stage pharmaceutical business. In other words, MyMD sits in the risk-heavy segment of the healthcare sector where clinical execution and financing discipline are critical. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex99-2.htm?utm_source=openai)) MyMD has also emphasized intellectual-property protection, with SEC disclosures referencing a portfolio of granted patents and pending applications intended to support its autoimmune and anti-aging programs. At the same time, the company operates in a highly competitive environment dominated by large pharmaceutical companies, specialty biotech peers, academic institutions, and public and private research organizations. That competitive backdrop means the investment case is driven by differentiation in mechanism of action, efficacy, tolerability, and patent protection. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1321834/000149315221012042/ex99-2.htm?utm_source=openai)) Geographically, the company’s roots are in Florida, but later SEC disclosures describe its combined company as being headquartered in Baltimore, Maryland. For investors in France, Belgium, and Switzerland, the key point is that this is a U.S.-listed issuer, historically quoted on NASDAQ, with a business profile typical of a micro-cap biotech: scientifically ambitious, capital-intensive, and highly sensitive to trial results, financing events, and corporate restructuring. A notable recent corporate event was the July 2024 ticker change from MYMD to TNFA, which signaled a broader repositioning of the business and its market identity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1321834/000149315223010384/form10-k.htm))